Flow cytometry is a critical tool for cancer research. It is used to identify, track and purify specific cell populations, assess cell cycle progression and apoptosis responses, and to support a broad range of engineering approaches such as the quantification of delivery systems and the development of novel protein labeling and imaging technologies. The Koch Institute Flow Cytometry Core is a Shared Resource that provides Center Members training in, and access to, state-of-the-art instrumentation, data analysis and technical expertise in cell sorting and analyses. In the current period, the capabilities of this Core were further expanded and enhanced. This includes moving into a larger, custom-designed space in the new Koch Institute building, an increase in the Core staff and the acquisition of new instrumentation. Notably, in the same period, there has been a substantial increase in the number of Center Members who use the Flow Cytomtery Core from 78% to 94%, including investigators from all four Programs. Thus, this Shared Resource is essential to the success of the Koch Institute mission. In the upcoming period, the Flow Cytometry Core will continue to offer a wide range of state-of-the-art services to support the research programs of Center Members. Additionally, the Core plans to make new instrument purchases, with the support of MIT funds, and establish cutting edge single cell technologies, with the support of requested developmental funds. In spite of the major expansion in services and the resulting increased costs of running this Core, the requested CCSG budget for Year 44 is slightly reduced from the requested and recommended budget in Year 39.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014051-47
Application #
9487932
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
47
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Massachusetts Institute of Technology
Department
Type
DUNS #
001425594
City
Cambridge
State
MA
Country
United States
Zip Code
Guner-Ataman, Burcu; González-Rosa, Juan Manuel; Shah, Harsh N et al. (2018) Failed Progenitor Specification Underlies the Cardiopharyngeal Phenotypes in a Zebrafish Model of 22q11.2 Deletion Syndrome. Cell Rep 24:1342-1354.e5
Phizicky, David V; Berchowitz, Luke E; Bell, Stephen P (2018) Multiple kinases inhibit origin licensing and helicase activation to ensure reductive cell division during meiosis. Elife 7:
Kowalski, Piotr S; Capasso Palmiero, Umberto; Huang, Yuxuan et al. (2018) Ionizable Amino-Polyesters Synthesized via Ring Opening Polymerization of Tertiary Amino-Alcohols for Tissue Selective mRNA Delivery. Adv Mater :e1801151
Kauffman, Kevin J; Oberli, Matthias A; Dorkin, J Robert et al. (2018) Rapid, Single-Cell Analysis and Discovery of Vectored mRNA Transfection In Vivo with a loxP-Flanked tdTomato Reporter Mouse. Mol Ther Nucleic Acids 10:55-63
Guen, Vincent J; Edvardson, Simon; Fraenkel, Nitay D et al. (2018) A homozygous deleterious CDK10 mutation in a patient with agenesis of corpus callosum, retinopathy, and deafness. Am J Med Genet A 176:92-98
Murphy, Patrick A; Butty, Vincent L; Boutz, Paul L et al. (2018) Alternative RNA splicing in the endothelium mediated in part by Rbfox2 regulates the arterial response to low flow. Elife 7:
Khan, Omar F; Kowalski, Piotr S; Doloff, Joshua C et al. (2018) Endothelial siRNA delivery in nonhuman primates using ionizable low-molecular weight polymeric nanoparticles. Sci Adv 4:eaar8409
Woolston, Benjamin M; Roth, Timothy; Kohale, Ishwar et al. (2018) Development of a formaldehyde biosensor with application to synthetic methylotrophy. Biotechnol Bioeng 115:206-215
Huang, Hsin-Ho; Qian, Yili; Del Vecchio, Domitilla (2018) A quasi-integral controller for adaptation of genetic modules to variable ribosome demand. Nat Commun 9:5415
Guimarães, Pedro P G; Gaglione, Stephanie; Sewastianik, Tomasz et al. (2018) Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy. ACS Nano 12:912-931

Showing the most recent 10 out of 904 publications